Icosapent ethyl vs mixed omega-3: reconciling REDUCE-IT and STRENGTH

← Back to articles

The two largest cardiovascular outcomes trials of high-dose omega-3 fatty acids reached opposite conclusions within two years of each other. REDUCE-IT reported a 25% relative reduction in major adverse cardiac events with 4 g/day of purified eicosapentaenoic acid (EPA) as the ethyl ester. STRENGTH, testing 4 g/day of a mixed EPA and docosahexaenoic acid (DHA) carboxylic acid formulation against a corn-oil comparator, was stopped early for futility. The contradiction is not fully resolved, and it matters because it shapes who, if anyone, should take high-dose omega-3 for heart protection — and makes clear that ordinary fish-oil supplements are not the same thing as either trial drug.

What the two trials tested

REDUCE-IT randomized 8,179 statin-treated patients with elevated triglycerides (135–499 mg/dL) and established cardiovascular disease or diabetes plus risk factors to icosapent ethyl 4 g/day or a mineral-oil placebo. After a median of 4.9 years, the primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) occurred in 17.2% of the icosapent group versus 22.0% of placebo (hazard ratio 0.75, 95% CI 0.68–0.83) [1]. STRENGTH randomized 13,078 broadly similar high-risk statin-treated patients to 4 g/day of a mixed EPA/DHA carboxylic acid (omega-3 CA) or corn oil. It was halted early at an interim analysis; the primary endpoint occurred in 12.0% on omega-3 CA versus 12.2% on corn oil (HR 0.99, 95% CI 0.90–1.09) — flatly null [2].

Three leading explanations

The first is the active-ingredient hypothesis: that purified EPA confers a benefit that adding DHA dilutes or offsets. The Japan EPA Lipid Intervention Study (JELIS) supports a role for EPA — 18,645 hypercholesterolemic patients given 1,800 mg/day of EPA plus a statin had a 19% relative reduction in major coronary events versus statin alone [3] — and DHA tends to raise LDL cholesterol more than EPA does. The second is the placebo/comparator hypothesis: REDUCE-IT used mineral oil, and some observers argued that small adverse effects of mineral oil on the control group could have inflated the apparent treatment benefit, whereas STRENGTH's corn oil was a more neutral comparator. The third is pharmacokinetic: achieved on-treatment EPA blood levels were much higher in REDUCE-IT than in STRENGTH, so the trials may simply have delivered different EPA exposures. None of these alone fully accounts for the gap, and they are not mutually exclusive.

The placebo/comparator controversy

This is the most-debated point, and the evidence cuts both ways. In REDUCE-IT, the mineral-oil placebo arm showed modest rises in LDL cholesterol and high-sensitivity C-reactive protein over follow-up, which critics argued could exaggerate the relative benefit of icosapent. A subsequent review of 80 studies that used mineral-oil placebos (authored partly by the drug's sponsor, so not a neutral source) concluded that biomarker changes attributable to mineral oil were inconsistent and generally not statistically or clinically meaningful, and that mineral oil did not appear to impair statin or nutrient absorption at the quantities used [4]. The honest reading is that a portion — but not all — of REDUCE-IT's effect could plausibly be comparator-related, the magnitude of any such artifact is disputed, and the trial drug retains FDA approval for cardiovascular risk reduction.

Why STRENGTH did not necessarily bury the EPA hypothesis

STRENGTH tested a different molecule (a mixed EPA/DHA carboxylic acid, not purified EPA ethyl ester) in a different formulation, and its primary comparison was active drug versus corn oil — not purified EPA versus mixed omega-3 head-to-head. A prespecified secondary analysis of STRENGTH found that even among patients who achieved the highest blood levels of EPA or of DHA, there was no signal of benefit versus corn oil (adjusted HR ~0.98 for EPA and ~1.02 for DHA) [5]. That weakens, but does not eliminate, the pure-EPA argument: STRENGTH shows that this specific formulation did not help its specific population, while leaving open whether purified EPA at REDUCE-IT-level exposures behaves differently.

What this means for supplement users

Icosapent ethyl is a prescription drug, not a dietary supplement. Its 4 g/day dose delivers roughly 4,000 mg of a single purified fatty acid — far more than, and chemically distinct from, what over-the-counter fish oil provides. Most retail fish-oil capsules contain only a few hundred milligrams of combined EPA and DHA, so reaching REDUCE-IT-comparable EPA exposure with consumer products is impractical and would also load substantial DHA, which the outcomes trials do not show to be protective. There is no FDA-recognized cardiovascular-event indication for over-the-counter fish oil, and it should not be substituted for the prescription product when the goal is event reduction.

The atrial-fibrillation trade-off

High-dose omega-3 is not risk-free. In REDUCE-IT, hospitalization for atrial fibrillation or flutter was more common with icosapent than placebo (3.1% vs 2.1%) [1]. A 2021 meta-analysis of seven cardiovascular outcomes trials (81,210 patients) found that marine omega-3 supplementation raised the risk of atrial fibrillation (HR 1.25, 95% CI 1.07–1.46), with a clear dose-response — the risk was higher in trials testing more than 1 g/day (HR 1.49) than at lower doses (HR 1.12) [6]. Anyone considering gram-level doses should weigh this against the potential benefit, particularly if they have a history of arrhythmia.

Where guidance currently stands

For triglyceride lowering, the 2019 American Heart Association science advisory concluded that prescription omega-3 at 4 g/day — whether EPA-only or EPA+DHA — is an effective and safe option, noting that EPA-only does not raise LDL cholesterol the way EPA+DHA can, and that the cardiovascular benefit for high-risk statin-treated patients is supported chiefly by REDUCE-IT's 25% event reduction [7]. The practical upshot: purified EPA (icosapent ethyl) has the strongest, though contested, outcomes evidence; mixed prescription omega-3 remains useful for lowering triglycerides but did not reduce events in STRENGTH; and routine over-the-counter fish oil sits below both, with no proven event benefit at typical consumer doses and a dose-dependent atrial-fibrillation signal at high doses.

Sources

1. Bhatt DL, Steg PG, Miller M, et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." N Engl J Med, 2019;380(1):11-22. PMID 30415628.
2. Nicholls SJ, Lincoff AM, Garcia M, et al. "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial." JAMA, 2020;324(22):2268-2280. PMID 33190147.
3. Yokoyama M, Origasa H, Matsuzaki M, et al. "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis." Lancet, 2007;369(9567):1090-1098. PMID 17398308.
4. Olshansky B, Chung MK, Budoff MJ, et al. "Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies." Eur Heart J Suppl, 2020;22(Suppl J):J34-J48. PMID 33061866.
5. Nissen SE, Lincoff AM, Wolski K, et al. "Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial." JAMA Cardiol, 2021;6(8):910-917. PMID 33993205.
6. Gencer B, Djousse L, Al-Ramady OT, et al. "Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis." Circulation, 2021;144(25):1981-1990. PMID 34612056.
7. Skulas-Ray AC, Wilson PWF, Harris WS, et al. "Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association." Circulation, 2019;140(12):e673-e691. PMID 31422671.